Últimas noticias sobre Biogen (NASDAQ:BIIB) Bolsa

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Inc

BIOGEN ORD

In the preceding three months, 17 analysts have released ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $253.47, a high estimate of $300.00, and a low estimate of $180.00. Experiencing a 5.09% decline, the current average is now lower than the previous average price target of $267.06. 
<img src="https://www.benzinga.com/files/images/story/2024/1730736056_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Biogen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Biogen's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Biogen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Delving into Biogen's Background</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Understanding the Numbers: Biogen's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Biogen displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 0.04%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biogen's net margin excels beyond industry benchmarks, reaching 15.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 2.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's ROA stands out, surpassing industry averages. With an impressive ROA of 1.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Biogen's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BIIB

Evaluating Biogen: Insights From 17 Financial Analysts

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $220 to $210.

News

Price Target

JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $210

The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils&#x2A; which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.

Reported Earlier, Eisai And Submit LEQEMBI BLA For Subcutaneous Alzheimer's Treatment To FDA, Targeting Early Disease Stages

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $270 to $255.

Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $255

Barclays analyst Carter Gould maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $190 to $180.

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $180

Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported upbeat earnings for the third <a href="https://www.benzinga.com/quote/biib/earnings">quarter on Wednesday</a>.
The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company reported sales of $2.47 billion, down 3% year over on constant currency and reported basis, beating the consensus of $2.43 billion.
Biogen raised its 2024 adjusted EPS guidance to $16.10-$16.60 versus prior guidance of $15.75-$16.25 and consensus of $16.19. Biogen continues to expect 2024 revenue to decline by a low-single-digit percentage, with core pharmaceutical revenue to be relatively flat compared to 2023, as further declines in multiple sclerosis product revenues are expected to be offset by increases in revenue from new product launches.
For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with mid-single digit percentage point operating margin improvement
Biogen shares fell 2.5% to trade at $176.55 on Thursday.
These analysts made changes to their price targets on Biogen following earnings announcement.
<ul>
<li>Morgan Stanley analyst Matthew Harrison downgraded Biogen from Overweight to Equal-Weight and lowered the price target from $285 to $204.</li>
<li>TD Cowen analyst Phil Nadeau maintained the stock with a Buy and lowered the price target from $300 to $275.</li>
<li>Needham analyst Ami Fadia reiterated Biogen with a Buy and maintained a $270 price target.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein reiterated Biogen with a Buy and maintained a $300 price target.</li>
</ul>
Considering buying BIIB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31132712/image-334-1024x556.png" alt="" class="wp-image-624499" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31132712/image-334-1024x556.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31132712/image-334-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31132712/image-334-768x417.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31132712/image-334.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41652163/jim-cramer-this-financial-stock-is-one-of-the-most-consistent-great-companies">Jim Cramer: This Financial Stock Is &#8216;One Of The Most Consistent, Great Companies&#8217;</a></li>
</ul>

Earnings

Markets

Trading Ideas

Biogen Analysts Slash Their Forecasts After Q3 Results

TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $300 to $275.

TD Cowen Maintains Buy on Biogen, Lowers Price Target to $275

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584eee82ee7bf60001abdc0e/stephen-powers">Deutsche Bank analyst Stephen Powers</a> downgraded the rating for The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) from Buy to Hold and lowered the price target from $39 to $35. Kraft Heinz shares closed at $33.73 on Wednesday. <a href="https://www.benzinga.com/quote/KHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Matthew Harrison downgraded Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Overweight to Equal-Weight and lowered the price target from $285 to $204. Biogen shares closed at $181.18 on Wednesday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33185064ed0001730304/john-ivankoe">JP Morgan analyst John Ivankoe</a> downgraded the rating for Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) from Overweight to Neutral but raised the price target from $67 to $100. Brinker shares closed at $104.25 on Wednesday. <a href="https://www.benzinga.com/quote/EAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Sara Russo downgraded Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) from Market Perform to Underperform and maintained the price target of $100. ARM Holdings shares closed at $154.40 on Wednesday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d52968b85e930001416e52/jim-kelleher">Argus Research analyst Jim Kelleher</a> downgraded the rating for Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) from Buy to Hold. Super Micro Computer shares closed at $33.07 on Wednesday. <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KHC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31114533/image-329-1024x566.png" alt="" class="wp-image-624262" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31114533/image-329-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31114533/image-329-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31114533/image-329-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31114533/image-329.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>

Downgrades

SMCI

This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and maintains $300 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $300 Price Target

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and maintains $270 price target.

Needham Reiterates Buy on Biogen, Maintains $270 Price Target

Morgan Stanley analyst Matthew Harrison downgrades Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Overweight to Equal-Weight and lowers the price target from $285 to $204.

Morgan Stanley Downgrades Biogen to Equal-Weight, Lowers Price Target to $204

New testing method highlights link between protofibrils and biomarkers for neurodegeneration- -Patient and caregiver perspectives on five-year treatment with lecanemab - - Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-

Reported Earlier, Eisai And Biogen Reveal Five-Year Findings On Alzheimer's Treatment Lecanemab At Clinical Trials for Alzheimer's Disease Conference

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.
Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.
Goldman Sachs notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.
Truist notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.
They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.
The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.
For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.
A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and Perspective Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).
Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.
A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and Regeneron Pharmaceuticals Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.
Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, Abbvie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).
Price Action: NVS stock is down 0.48% at $110.00 at last check Wednesday.
Photo by Taljat David via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></li>
</ul>

Analyst Color

Biotech

Equities

Large Cap

Health Care

General

ABBV

AMGN

CATX

INCY

KYMR

REGN

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

On Wednesday,&nbsp;Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;reported third-quarter adjusted EPS of $4.08, down 6%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.79</a>.
The company&nbsp;<a target="_blank" href="https://investors.biogen.com/static-files/75f1044b-a254-48e9-acdb-bcb0263930b0" rel="noreferrer noopener">reported</a> sales of&nbsp;$2.47 billion, down 3% year over on constant currency and reported basis, beating the consensus of $2.43 billion.
Multiple sclerosis revenue of $1.05 billion decreased by 9% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $406.1 million from $456.3 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate</a>
Rare disease revenue&nbsp;increased&nbsp;10% year over year (up 10% CC) to $495 million.
Spinraza&#8217;s revenue fell to $381.4 million from $448.2 million a year ago.
Revenues from Skyclarys, acquired via Reata acquisition, reached $102.3 million during the quarter.
In Alzheimer&#8217;s disease, Biogen said Leqembi third quarter global in-market sales of approximately $67 million, including U.S. in-market sales of approximately $39 million; E.U. CHMP re-examination expected to be completed this year.
Postpartum depression drug Zurzuvae&#8217;s third-quarter sales reached $22 million.
Guidance: Biogen raised its 2024 adjusted EPS guidance to $16.10-$16.60&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40105919/biogen-q2-earnings-beats-consensus-lifts-2024-profit-forecast-as-new-drug-launches-expected-to-of" rel="noreferrer noopener">versus prior guidance</a> of $15.75-$16.25 and consensus of $16.19.
Biogen continues to expect 2024 revenue to decline by a low-single-digit percentage, with core pharmaceutical revenue to be relatively flat compared to 2023, as further declines in multiple sclerosis product revenues are expected to be offset by increases in revenue from new product launches.
For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with mid-single digit percentage point operating margin improvement.
Price Action: BIIB stock is down 1.37% at $180.95&nbsp;at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" target="_blank" rel="noreferrer noopener">GSK&#8217;s Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024</a></li>
</ul>

Guidance

Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook

<ul>
<li>Biogen continues to expect total revenue to decline by a low-single digit percentage, with core pharmaceutical revenue, defined as product revenue plus Biogen's 50% share of net LEQEMBI product revenue and cost of sales, including royalties, to be relatively flat for 2024 compared to 2023 as further declines in multiple sclerosis product revenue are expected to be offset by increases in revenue from new product launches.&nbsp;</li>
<li>Biogen continues to expect an improvement in the cost of sales as a percentage of total revenue for 2024 compared to 2023 driven by product mix and significantly lower idle capacity charges.&nbsp;</li>
<li>For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with midsingle digit percentage point operating margin improvement. This is expected to be driven by improved cost of sales as a percentage of revenue, as well as lower operating expenses as a result of the Company's Fit for Growth and R&amp;D prioritization initiatives</li>
</ul>

Biogen Raised Its 2024 Adjusted EPS Guidance To $16.10-$16.60 Versus Prior Guidance Of $15.75-$16.25 And Consensus Of $16.19

Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported quarterly earnings of $4.08 per share which beat the analyst consensus estimate of $3.79 by 7.65 percent. This is a 6.42 percent decrease over earnings of $4.36 per share from the same period last year. The company reported quarterly sales of $2.47 billion which beat the analyst consensus estimate of $2.43 billion by 1.30 percent. This is a 2.53 percent decrease over sales of $2.53 billion the same period last year.

Biogen Q3 2024 Adj EPS $4.08 Beats $3.79 Estimate, Sales $2.47B Beat $2.43B Estimate

Neomorph will receive an upfront payment and is eligible to receive contingent milestone payments per target as the collaboration progresses through various stages.&nbsp;
These include certain pre-clinical milestones payable in the near-term and certain clinical, regulatory, commercial and sales milestones that are anticipated to occur later this decade and beyond, for a total consideration of up to $1.45B.&nbsp;
Biogen will reimburse Neomorph for certain research development costs. Neomorph is also eligible to receive potential future royalties in the mid-single digit to low double-digit range.

Biogen, Neomorph Enter Research Collaboration To Discover And Develop Molecular Glue Degraders For Priority Targets In Alzheimer's, Rare Neurological, And Immunological Diseases

Management

Executive Vice President And CFO Michael McDonnell To Retire in February 2025; Robin Kramer To Assume Role As CFO

<ul>
<li>The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab</li>
<li>Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 development</li>
<li>IgA Nephropathy (IgAN) is a leading cause of chronic kidney disease with up to&nbsp;40%&nbsp;of IgAN patients progressing to end stage kidney disease about 20 years after diagnosis</li>
</ul>

Reported Saturday, Biogen Revealed Results From Phase 2 IGNAZ Study Of Felzartamab In IgA Nephropathy At ASN Kidney Week 2024

Barclays analyst Carter Gould maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $180.00. The company's sh...

Barclays Sticks to Its Hold Rating for Biogen (BIIB)

Bank of America Securities analyst Jason Zemansky has reiterated their neutral stance on BIIB stock, giving a Hold rating today. Jason Zemansky has...

Cautious Neutrality: Biogen's Mixed Performance and Uncertain Growth Outlook

TD Cowen lowered the firm's price target on Biogen (BIIB) to $275 from $300 and keeps a Buy rating on the shares. The firm said they reported Q3 re...

Biogen price target lowered to $275 from $300 at TD Cowen

Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on BIIB stock, giving a Buy rating today. Sumant Kulkarni's rating is...

Biogen's Promising Potential: Strong Financial Performance and Strategic Growth Opportunities Justify Buy Rating

Oppenheimer lowered the firm's price target on Biogen (BIIB) to $255 from $270 and keeps an Outperform rating on the shares. The firm notes Biogen ...

Biogen price target lowered to $255 from $270 at Oppenheimer

Biogen slips as Morgan Stanley downgrades on Leqembi launch

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Microsoft (MSFT) reported better-than-...

Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz

How is QQQ stock faring? The Invesco QQQ ETF is down 2.67% in the past five days but has risen about 19% year-to-date.   According to TipRanks' uni...

QQQ ETF Update, 11/1/2024

Executive reshuffles: BIIB, USB and WES

Bullish option flow detected in Biogen (BIIB) with 2,803 calls trading, 2x expected, and implied vol increasing over 2 points to 32.79%. Jan-26 110...

Biogen call volume above normal and directionally bullish

ABNB

APTV

ATEC

CMCSA

CMPS

ESAIY

ESALF

LMND

MRNA

MSFT

NVCR

NVDA

ODFL

PAYX

PLNT

PTON

RBLX

RIVN

ROOT

SBUX

SIMO

SSNLF

TSLA

UBER

VWAGY

VWAPY

WING

Press Releases

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases

Legal

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Comments

Biogen

Noticias

Últimas noticias sobre Biogen (NASDAQ:BIIB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL